Free US stock correlation to major indices and sector benchmarks for performance attribution analysis and return source identification. We help you understand how your portfolio moves relative to broader market benchmarks and identify return drivers. We provide correlation analysis, attribution breakdown, and benchmark comparison for comprehensive coverage. Understand performance drivers with our comprehensive correlation and attribution analysis tools for portfolio optimization.
This analysis covers recent trading activity for Erasca Inc. (ERAS), a clinical-stage oncology biotech firm, as of the April 18, 2026 trading session. ERAS closed at $19.01, marking a 4.28% gain in the latest session, outperforming the average return of its peer group for the same trading period. No recent earnings data is available for ERAS as of this analysis, so recent price moves are primarily driven by broader sector sentiment and technical positioning. Key takeaways from this analysis incl
Erasca (ERAS) Stock Iron Condor (+4.28%) 2026-04-18 - Reversal Picks
ERAS - Stock Analysis
4671 Comments
1795 Likes
1
Subira
Community Member
2 hours ago
Trading ranges are wide today, reflecting heightened uncertainty and cautious investor behavior.
👍 126
Reply
2
Lemonica
Returning User
5 hours ago
Not sure what I expected, but here we are.
👍 215
Reply
3
Chael
Active Reader
1 day ago
This feels like something just started.
👍 190
Reply
4
Ayahna
Influential Reader
1 day ago
I’m agreeing out of instinct.
👍 84
Reply
5
Mikayleigh
Insight Reader
2 days ago
This deserves endless applause. 👏
👍 297
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.